Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
'Derek's visionary leadership and unwavering values have shaped Castle Biosciences into what it is today: a company focused on improving patient outcomes through innovative diagnostic tests for skin cancers, Barrett's esophagus and uveal melanoma,' said Frank Stokes, chief financial officer of Castle Biosciences. 'Over nearly two decades, his leadership approach has exemplified how great vision and values can drive meaningful progress – building a company culture where patient needs remain at the center of strategic decisions and where personalized disease insights can translate into better care for those who need it most.'
'I am truly honored to receive this recognition from the Houston Business Journal,' said Maetzold. "This award validates our core belief that lasting impact comes from doing right by our team and never losing sight of the patients who depend on our work.'
The award recipients will be honored at a special event held by the Houston Business Journal in August.
About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Investor Contact:Camilla Zuckeroczuckero@castlebiosciences.com
Media Contact:Allison Marshallamarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/ebd01c42-a4d1-47f5-a4e1-5d0f87e16e3a
https://www.globenewswire.com/NewsRoom/AttachmentNg/510a258d-2263-40b2-a51a-947dd2e15f23Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
BrightSpring Health Services Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
BrightSpring Health Services (NASDAQ:BTSG) Second Quarter 2025 Results Key Financial Results Revenue: US$3.15b (up 15% from 2Q 2024). Net income: US$9.21m (down 54% from 2Q 2024). Profit margin: 0.3% (down from 0.7% in 2Q 2024). EPS: US$0.046 (down from US$0.10 in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period BrightSpring Health Services Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 5.3%. Earnings per share (EPS) missed analyst estimates by 9.3%. Looking ahead, revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Healthcare industry in the US. Performance of the American Healthcare industry. The company's shares are down 4.3% from a week ago. Risk Analysis What about risks? Every company has them, and we've spotted 3 warning signs for BrightSpring Health Services (of which 1 is a bit unpleasant!) you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Universal Display Second Quarter 2025 Earnings: Beats Expectations
Universal Display (NASDAQ:OLED) Second Quarter 2025 Results Key Financial Results Revenue: US$171.8m (up 8.4% from 2Q 2024). Net income: US$67.3m (up 29% from 2Q 2024). Profit margin: 39% (up from 33% in 2Q 2024). The increase in margin was primarily driven by higher revenue. EPS: US$1.41 (up from US$1.10 in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Universal Display Revenues and Earnings Beat Expectations Revenue exceeded analyst estimates by 6.8%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Semiconductor industry in the US. Performance of the American Semiconductor industry. The company's shares are down 2.8% from a week ago. Balance Sheet Analysis While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Universal Display's balance sheet and an in-depth analysis of the company's financial position. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Ramaco Resources Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Ramaco Resources (NASDAQ:METC) Second Quarter 2025 Results Key Financial Results Revenue: US$153.0m (down 1.5% from 2Q 2024). Net loss: US$14.0m (down by 381% from US$4.98m profit in 2Q 2024). US$0.26 loss per share (down from US$0.097 profit in 2Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Ramaco Resources Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) missed analyst estimates by 47%. Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Metals and Mining industry in the US. Performance of the American Metals and Mining industry. The company's shares are down 16% from a week ago. Risk Analysis Before we wrap up, we've discovered 2 warning signs for Ramaco Resources (1 can't be ignored!) that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Effettua l'accesso per consultare il tuo portafoglio
